查看文章

We report herein the 10‐year outcome of the Tor Vergata weaning off immunosuppression protocol in hepatitis C virus (HCV) liver transplant patients. Thirty‐four patients who had received a liver graft for HCV‐related cirrhosis were enrolled in a prospective study in which they were progressively weaned off immunosuppression. The primary endpoints were feasibility and safety of the weaning; the second aim was to assess fibrosis progression. At the 10‐year follow‐up, of the eight original tolerant patients, six remained IS‐free. Of the 26 individuals who could not be weaned, 22 were alive. When the baseline biopsies were compared with the 10‐year biopsies, the tolerant group showed no differences in staging, whereas the nontolerant group showed a significant increase in staging. The fibrosis progression rates calculated for the tolerant and the nontolerant groups were −0.06 ± 0.12 and 0.1 ± 0.2, respectively (P …